HealthQuill Biogen Inc
Biogen Inc., a US-based biotechnology company, will acquire Reata Pharmaceuticals for $7.3 billion to expand its neurological portfolio, according to a company statement
Drugs Health Pharma

Biogen Inc. to buy US-based Reata Pharmaceuticals for $7.3 billion

HQ Team July 29, 2023: Biogen Inc., a US-based biotechnology company, will acquire Reata Pharmaceuticals for $7.3 billion to expand its neurological portfolio,.

Read More
Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority for leqembi, an investigational drug to treat early onset of Alzheimer’s disease.
Drugs Health Medical Pharma

Japan’s Eisai seeks marketing nod for Alzheimer’s drug in South Korea

HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.

Read More
The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral sclerosis (ALS), an aggressive and rare form of the disease in adults.
Drugs Health Medical Pharma

Biogen’s sclerosis drug gets FDA’s fast approval clearance

HQ Team April 26, 2023: The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral.

Read More
The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.
Drugs Pharma

FDA gives accelerated approval for Alzheimer’s drug

The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.

Read More